Fosgonimeton in mild-to-moderate Alzheimer's disease
Fosgonimeton did not significantly improve ADAS-Cog11 or ADCS-ADL23 versus placebo. However, the consistently observed non-significant improvements favoring fosgonimeton suggests potentially relevant biological activity with fosgonimeton and that positive modulation of HGF signaling may impact components of the pathophysiologic processes of neurodegenerative diseases.
Authors
- Kevin J. Church
- Hans J. Moebius (ORCID: https://orcid.org/0000-0002-6311-0157)
- Pierre N. Tariot (ORCID: https://orcid.org/0000-0002-6058-8032)
- Michael Hale (ORCID: https://orcid.org/0000-0002-6890-196X)
- Richard Holub
- Kai‐Bin C. Ooi (ORCID: https://orcid.org/0009-0000-4030-6790)
- Anton P. Porsteinsson (ORCID: https://orcid.org/0000-0002-0166-1738)
- Marwan N. Sabbagh (ORCID: https://orcid.org/0000-0001-8139-3309)
- Javier San Martin (ORCID: https://orcid.org/0009-0003-5127-2129)
- Simon Daggett (ORCID: https://orcid.org/0009-0001-7098-0492)
Institutions
- Alzheimer's Association (US)
- Barrow Neurological Institute (US)
- St. Joseph's Hospital and Medical Center (US)
- University of Arizona (US)
- Banner Health (US)
- Athira Pharma (United States) (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Capital Cardiology Associates (US)
- University of Rochester (US)
Publication Details
- Journal
- Journal of Alzheimer s Disease Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/25424823251405817
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00